Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting

被引：0
|
作者：
Janapala, Rajesh Naidu [1 ]
Patel, Jigar [1 ]
Belfaqeeh, Omar [1 ]
Pourmand, Ali [1 ]
机构：
[1] George Washington Univ, Int Med Program, Sch Med & Hlth Sci, Washington, DC USA
来源：
INTERNATIONAL IMMUNOPHARMACOLOGY | 2021年 / 101卷
关键词：
Mild COVID-19; Hydroxychloroquine; HCQ; Hospitalization; Mortality;
D O I：
10.1016/j.intimp.2021.107878
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We appreciate the efforts of the authors in their study on the clinical outcome of hydroxychloroquine (HCQ) therapy in mild coronavirus disease 2019 (COVID-19) (Mokhtari et al., 2021). We would like to make some comments based on our understanding of the study.
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
    Mokhtari, Majid
    Mohraz, Minoo
    Gouya, Mohammad Mehdi
    Tabar, Hengameh Namdari
    Tabrizi, Jafar-Sadegh
    Tayeri, Katayoun
    Aghamohamadi, Saeide
    Rajabpoor, Zahra
    Karami, Manoochehr
    Raeisi, Alireza
    Rahmani, Hamid
    Khalili, Hossein
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 96
  • [2] No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
    Sands, Kenneth
    Wenzel, Richard
    McLean, Laura
    Korwek, Kimberly
    Roach, Jonathon
    Miller, Karla
    Poland, Russell E.
    Burgess, L. Hayley
    Jackson, Edmund
    Perlin, Jonathan B.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 104 : 34 - 40
  • [3] Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19
    Lofgren, Sarah M.
    Nicol, Melanie R.
    Bangdiwala, Ananta S.
    Pastick, Katelyn A.
    Okafor, Elizabeth C.
    Skipper, Caleb P.
    Pullen, Matthew F.
    Engen, Nicole W.
    Abassi, Mahsa
    Williams, Darlisha A.
    Nascene, Alanna A.
    Axelrod, Margaret L.
    Lother, Sylvian A.
    MacKenzie, Lauren J.
    Drobot, Glen
    Marten, Nicole
    Cheng, Matthew P.
    Zarychanshi, Ryan
    Schwartz, Ilan S.
    Silverman, Michael
    Chagla, Zain
    Kelly, Lauren E.
    McDonald, Emily G.
    Lee, Todd C.
    Hullsiek, Kathy H.
    Boulware, David R.
    Rajasingham, Radha
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (11):
  • [4] Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
    Lamback, Elisa Baranski
    de Oliveira, Monica Amorim
    Haddad, Andrea Ferreira
    Marcondes Vieira, Andre Filipe
    Ferreira Neto, Armando Leao
    Maia, Taciana da Silva
    Chrisman, Juliana de Rezende
    de Mello Spineti, Pedro Pimenta
    de Mattos, Marco Antonio
    Costa, Eduardo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2021, 25 (02):
  • [5] Hydroxychloroquine in the COVID-19 treatment
    Santiesteban Vazquez, Viana Elina
    Castro Barberena, Adys
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2021, 19 (06): : 898 - 899
  • [6] Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
    Hamid Rahmani
    Effat Davoudi-Monfared
    Anahid Nourian
    Morteza Nabiee
    Setayesh Sadeghi
    Hossein Khalili
    Ladan Abbasian
    Fereshteh Ghiasvand
    Arash Seifi
    Malihe Hasannezhad
    Sara Ghaderkhani
    Mostafa Mohammadi
    Mir Saeed Yekaninejad
    DARU Journal of Pharmaceutical Sciences, 2020, 28 : 625 - 634
  • [7] Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
    Rahmani, Hamid
    Davoudi-Monfared, Effat
    Nourian, Anahid
    Nabiee, Morteza
    Sadeghi, Setayesh
    Khalili, Hossein
    Abbasian, Ladan
    Ghiasvand, Fereshteh
    Seifi, Arash
    Hasannezhad, Malihe
    Ghaderkhani, Sara
    Mohammadi, Mostafa
    Yekaninejad, Mir Saeed
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 28 (02) : 625 - 634
  • [8] Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance
    Rodrigues, Cristhieni
    Freitas-Santos, Rodrigo S.
    Levi, Jose Eduardo
    Senerchia, Andreza A.
    Lopes, Ana Tarina A.
    Santos, Sergio R.
    Siciliano, Rinaldo F.
    Pierrotti, Ligia C.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 58 (05)
  • [9] Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease
    Mallat, Jihad
    Hamed, Fadi
    Balkis, Maher
    Mohamed, Mohamed A.
    Mooty, Mohamad
    Malik, Asim
    Nusair, Ahmad
    Bonilla, Maria-Fernanda
    MEDICINE, 2020, 99 (52)
  • [10] COVID-19 and hypercoagulability in the outpatient setting
    Emert, Roger
    Shah, Payal
    Zampella, John G.
    THROMBOSIS RESEARCH, 2020, 192 : 122 - 123
12345